+44 (0)20 3910 4640 hello@symmetron.net

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Value in Health. 2017; 20(9):A427

Authors

Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A

Noteworthy

This is the first study to estimate the progression-related indirect and societal costs of HR+/HER2- metastatic breast cancer in the UK.

We developed a novel method to systematically search and screen both journal articles and grey literature.

Process

\

Systematic search of journal articles and grey literature reporting indirect costs associated with metastatic breast cancer (early mortality, productivity loss, replacement housework, childcare, informal care, lost leisure time,
and transportation).

\

Critical appraisal and extraction of relevant resource use estimates from the UK and other countries.

\

Costs were estimated per woman, per month, for two ‘health states’: stable and progressed disease.

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

Psoriasis

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

 

Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective